Health Condition 1: null- Tuberculous meningitis Health Condition 2: A170- Tuberculous meningitis
Conditions
Interventions
Intervention1: 12 months ATT(Group B): Group B
Intensive phase (2-3 months):
Rifampicin (R) (10 mg/kg/day) oral, usual 600 mg
Isoniazid (H)(5 mg/kg/day) oral, usual 300 mg
Pyrazinamide (Z) (20-25 mg/
Sponsors
Department of Health Research DHR
Eligibility
Inclusion criteria
Inclusion criteria: All of the following: 1. All patients with suspected tuberculous meningitis (TBM) according the criteria by Marais et al. (Marais et al., 2010b) 2. All stages of TBM will be included 3. Patients who consent for the study and consent to undergo CSF analysis
Exclusion criteria
Exclusion criteria: Any of the following: 1. Patients who have associated cryptococcal meningitis 2. Patient who are HIV positive 3. Patients with hepatic or renal dysfunction, organ transplantation, malignancy, pregnancy, lactation 4. Patients with age 5. Patients who have proven drug resistant tuberculosis and have to be instituted longer treatment 6. Patients refusing to consent for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Combined relapse and mortalityTimepoint: At one year follow up after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Other outcomes studied will be rate of relapse, mRS at at one year follow after after stopping treatmentTimepoint: 3, 6, 9, 12, 18 and 24 months | — |
Countries
India
Contacts
Public ContactDeepti Vibha
All India Institute of Medical Sciences
Outcome results
None listed